- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
C2 Antibody (N-term)Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab)
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AP10662a | 0.1 mg 400 ul | In Stock | $ 255.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
| AP10662a-ev20 | 20 ug 100 ul | In Stock | $ 95.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
C2 Antibody (N-term) - Product info | |
| Application | WB
|
| Primary Accession | P06681 |
| Other Accession | NP_000054 |
| Reactivity | Human, Hamster |
| Concentration | 0.25 mg/ml |
| Isotype | Rabbit Ig |
| Calculated MW | 83268 Da |
C2 Antibody (N-term) - Additional info | |
| Gene ID 717 | |
| Other Names C2; Complement C2; C3/C5 convertase; Complement C2b fragment; Complement C2a fragment | |
| Target/Specificity This C2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 150-180 amino acids from the N-terminal region of human C2. | |
| Dilution WB~~1:100~500WB~~1:1000 | |
| Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions C2 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures. | |
C2 Antibody (N-term) - Protein Information | |
| Name C2 | |
| Function Component C2 which is part of the classical pathway of the complement system is cleaved by activated factor C1 into two fragments: C2b and C2a. C2a, a serine protease, then combines with complement factor 4b to generate the C3 or C5 convertase | |
| Cellular Location Secreted. | |
C2 Antibody (N-term) - Related products
C2 Antibody (N-term) - Application data
-
C2 Antibody (N-term) (Cat. #AP10662a) western blot analysis in CHO cell line lysates (35ug/lane).This demonstrates the C2 antibody detected the C2 protein (arrow).
C2 Antibody (N-term) - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
Component C2 is a serum glycoprotein that functions as part of the classical pathway of the complement system. Activated C1 cleaves C2 into C2a and C2b. The serine proteinase C2a then combines with complement factor 4b to create the C3 or C5 convertase. Deficiency of C2 has been reported to associated with certain autoimmune diseases and SNPs in this gene have been associated with altered susceptibility to age-related macular degeneration. This gene localizes within the class III region of the MHC on the short arm of chromosome 6. Alternative splicing results in multiple transcript variants encoding distinct isoforms. Additional transcript variants have been described in publications but their full-length sequence has not been determined.
REFERENCES
Hu, M., et al. Pharmacogenet. Genomics 20(10):634-637(2010) Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010) Liu, X., et al. Retina (Philadelphia, Pa.) 30(8):1177-1184(2010) Han, S., et al. Hum. Immunol. 71(7):727-730(2010) Ishii, Y., et al. J. Immunol. 151(1):170-174(1993)
